Global Triamcinolone Acetonide Injection Market Size, Share and Trends Analysis Report, By Type (1 ml vial, 5 ml vial, and 10 ml vial), By Application (Arthritic Disorders, Dermatoses, Multiple Sclerosis, Allergic Conditions, and Others), and By Distribution Channel (Hospitals, Drug Stores, and Others), Forecast 2022-2028

The global triamcinolone acetonide injection market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). The synthetic corticosteroid, triamcinolone acetonide injection works by decreasing the release of chemicals that trigger allergies and other inflammatory responses. It can be used to treat asthma, chronic obstructive pulmonary disease (COPD), arthritis, and psoriasis in adults and children over the age of six. According to World Health Organization (WHO), asthma is the most common chronic disease among children. Asthma affected an estimated 262 million people in 2019 and caused 461000 deaths. Chronic Obstructive Pulmonary Disease (COPD) is the third leading cause of death worldwide, causing 3.23 million deaths in 2019. Over 80% of these deaths occurred in low- and middle-income countries.

Some major players in the market include G&W laboratories Inc., Lannett Co. Inc., Perrigo Co. PLC, Taro Pharmaceutical Industries Ltd., Mylan NV, Lupin Inc., and Teva Pharmaceutical Industries Ltd. among others. The market players are helping significantly in the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay in the competition of the market. For instance, in October 2021, Bausch + Lomb along with Bausch Health Companies Inc. and Clearside Biomedical, Inc., announced that the US Food and Drug Administration (FDA) has approved XIPERE (triamcinolone acetonide injectable suspension) for suprachoroidal use for the treatment of macular edema associated with uveitis, a form of eye inflammation. XIPERE is the first and only medicine to be approved in the US for delivery via suprachoroidal injection, a method designed to facilitate targeted delivery of therapeutic agents to the retina and choroid.

In December 2019, Flexion Therapeutics, Inc., announced that the US Food and Drug Administration (FDA) had approved a supplemental New Drug Application (NDA) to update the product label for ZILRETTA (triamcinolone acetonide extended-release injectable suspension) for the treatment of osteoarthritis (OA) knee pain.

Market Coverage

• The market number available for – 2022-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Type
  • By Application
  • By Distribution Channel
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape- G&W laboratories Inc., Lannett Co. Inc., Perrigo Co. PLC, Taro Pharmaceutical Industries Ltd., Mylan NV, Lupin Inc. and Teva Pharmaceutical Industries Ltd. among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Triamcinolone Acetonide Injection Market Report by Segment

By Type

• 1 ml vial
• 5 ml vial
• 10 ml vial

By Application

• Arthritic Disorders
• Dermatoses
• Multiple Sclerosis
• Allergic Conditions
• Others

By Distribution Channel

• Hospitals
• Drug Stores
• Others

Global Triamcinolone Acetonide Injection Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa